Rezolute announces initiation of phase 1 study of rz402, an oral plasma kallikrein inhibitor for the treatment of diabetic macular edema

Rz402 is a plasma kallikrein inhibitor being investigated as a potential once-daily, oral therapy for dme

RZLT Ratings Summary

RZLT Quant Ranking